VELA DIAGNOSTICS

Company Overview

Vela Diagnostics is developing and marketing an NGS portfolio of oncology and virology tests, with an emphasis on melanoma, NSCLC, colorectal cancer, and HCV genotyping.

Vela Diagnostics uses NGS and rtPCR technologies on its integrated Sentosa platform, providing a unique ability to use one system for two workflows.

In August 2020, Vela Diagnostics launched OncoKey SL 60 Plus Assay, an NGS-based, pan-cancer assay that detects SNVs, Indels, CNVs, MSI, fusions, and oncogenic pathogens in more than 60 genes. This assay is not liquid biopsy; it uses FFPE tissue specimens. The assay is available for research use only.

Vela Diagnostics markets a liquid biopsy kit, Sentosa SX cell-free DNA Extraction Kit, for use in NGS and PCR workflows. The kit recovers cfDNA and can run on the Sentosa SX101 instrument, which automates the extraction and NGS/PCR set up.

In January 2018, Vela Diagnostics licensed important liquid biopsy technology from the University of California, San Francisco (UCSF), covering the enrichment of rare sequences. The two technologies are Flash (Finding Low Abundance Sequences by Hybridization) and Dash (Depletion of Abundant Sequences by Hybridization). Flash can be used to enrich bacterial or viral antibiotic resistance genes by more than 10x. Dash is a single-tube process to deplete unwanted sequences.

In March 2022, Vela Diagnostics launched its new OncoKey SL 60 and 525 Plus Panels. These next-generation sequencing (NGS)-based panels are intended for detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens, for up to 64 samples in a single sequencing run.

In October 2023, Vela Diagnostics announced a research collaboration with SRL Inc, a premier Japanese healthcare service company. This partnership aims to facilitate the distribution of Vela Diagnostics’ cutting-edge molecular diagnostic solutions in Japan.

Company's Business Segments

• Laboratory Testing : The company generates revenue from various lab tests such as NGS, PCR, Labware, Consumables.
• Solutions : The company also provides solutions such as Next-Generation Sequencing, Near-Patient Testing, Real-Time PCR, Sentosa FLEX, Pharma Partnering.